# US 2019/0292267 A1 · Bispecific cxcr4-cd4 polypeptides with potent anti-hiv activity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0292267 A1
- Document ID: US20190292267A1
- Status: Published application
- Kind: A1
- Application number: 16/295,041
- Filed: 2019-03-07
- Published: 2019-09-26
- Earliest claimed: 2015-04-02
- Assignees: Ablynx N.V.
- Applicants: Ablynx N.V.
- Inventors: Hugo Soares; Dominique Schols; Peter Vanlandschoot; Philippe Van Rompaey; Catelijne Stortelers
- Web page: https://patentgrep.com/patent/US20190292267A1

## CPC

- C07K 16/2866: {against receptors for cytokines, lymphokines, interferons}
- A61K 39/39541: {against normal tissues, cells}
- A61K 47/60: the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A61P 31/18: for HIV
- C07K 16/18: against material from animals or humans
- C07K 16/2812: {against CD4}
- A61K 2039/507: {Comprising a combination of two or more separate antibodies}
- C07K 2317/31: multispecific
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/567: Framework region [FR]
- C07K 2317/569: Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to bispecific polypeptides that are directed against the cellular receptor CD4 as well as a cellular co-receptor for HIV. Said polypeptides may be used to prevent human cell entry of HIV.

## Claims

### Claim 1

Polypeptide comprising a first and a second immunoglobulin single variable domain (ISV), wherein
said first ISV binds to CD4 present on the surface of a cell; and
said second ISV binds to CXCR4 present on the surface of said cell.

### Claim 2

(canceled)

### Claim 3 (depends on 1)

The polypeptide according to claim 1, wherein said polypeptide inhibits infection of human immunodeficiency virus (HIV) or simian immunodeficiency virus (SIV).

### Claim 4 (depends on 3)

The polypeptide according to claim 3, wherein said HIV is chosen from the group consisting of HIV-1 and HIV-2.

### Claim 5 (depends on 1)

The polypeptide according to claim 1, wherein said cell is a human cell.

### Claim 6 (depends on 1)

The polypeptide according to claim 1, wherein said polypeptide prevents infection of said HIV for at least 3 months, such as at least 6 months, or even longer such as e.g. 9 m, 11 m, 1 y, 1.5 y, 2 y or even longer.

### Claim 7 (depends on 1)

The polypeptide according to claim 1, wherein said polypeptide inhibits HIV infection by about 10%, 20%, 30%, 40%, 50%, 60%, 80%, 90% and preferably 95% or more, such as 100%, for instance as measured in a HIV infection assay.

### Claim 8 (depends on 1)

The polypeptide according to claim 1, wherein said polypeptide inhibits HIV fusion with CD4+CXCR4+ cells.

### Claim 9 (depends on 1)

The polypeptide according to claim 1, wherein said polypeptide inhibits binding of a natural ligand to said CXCR4 by less than about 50%, such as 40%, 30%, or 20% or even less than 10%, such as less than 5%, wherein the natural ligand is Stromal Cell-Derived Factor-1 beta (SDF-1β) or Stromal Cell-Derived Factor-1 alpha (SDF-1α).

### Claim 10 (depends on 1)

The polypeptide according to claim 1, further comprising a serum protein binding moiety or PEG.

### Claim 11 (depends on 10)

The polypeptide according to claim 10, wherein said serum protein binding moiety is an immunoglobulin single variable domain binding serum albumin.

### Claim 12 (depends on 1)

Composition comprising a polypeptide according to claim 1.

### Claim 13 (depends on 1)

A method for inhibiting and/or preventing HIV infection in a human subject comprising administering to the human subject a polypeptide according to claim 1 in an amount effective to inhibit and/or prevent the HIV infection in the human subject.

### Claim 14 (depends on 13)

The method according to claim 13, wherein said polypeptide prevents HIV infection for at least 3 months, such as at least 6 months, or even longer such as e.g. 9 m, 11 m, 1 y, 1.5 y, 2 y or even longer.

### Claim 15 (depends on 13)

The method according to claim 13, wherein said polypeptide inhibits HIV infection by about 10%, 20%, 30%, 40%, 50%, 60%, 80%, 90% and preferably 95% or more, such as 100%, for instance as measured in a HIV infection assay.

### Claim 16 (depends on 13)

The method according to claim 13, wherein said polypeptide inhibits HIV fusion with CD4+CXCR4+ cells.

### Claim 17 (depends on 13)

The method according to claim 13, wherein said polypeptide inhibits binding of a natural ligand to said CXCR4 by less than about 50%, such as 40%, 30%, or 20% or even less than 10%, such as less than 5%, wherein the natural ligand is Stromal Cell-Derived Factor-1 beta (SDF-1β) or Stromal Cell-Derived Factor-1 alpha (SDF-1α).
